Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer

被引:4
作者
Kolwijck, Eva [1 ]
Span, Paul N. [2 ]
Thomas, Chris M. G. [1 ,2 ]
Bulten, Johan [3 ]
Sweep, Fred C. G. J. [2 ]
Massuger, Leon F. A. G. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
关键词
CA; 125; biomarker; ovarian cancer; ovarian carcinoma; cyst fluid; PREOPERATIVE SERUM CA-125; MONOCLONAL-ANTIBODY; HALF-LIFE; CARCINOMA; SURVIVAL; ANTIGEN; TUMORS; CA125;
D O I
10.3892/or_00000672
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most ovarian tumors contain ovarian cyst fluid (oCF) which can be easily obtained during surgery. This is the first study that explored if CA 125 in oCF Could be of prognostic value for patients with epithelial ovarian cancer (EOC). Of 54 patients with primary EOC, oCF and pre-operative serum were collected and clinicopathological data were retrospectively obtained. CA 125 was measured with the commercially available CA 125 assay. CA 125 in oCF (n=54, median: 55,500 U/ml, range: 590-10,200,000 U/ml) was always higher than in the corresponding serum (n=51, median: 179 U/ml, range: 13-11,000 U/ml) (p < 0.001) and values were moderately correlated (R=0.337, p=0.016). CA 125 in oCF was associated with histology (p < 0.001) and tumor grade (p=0.038). High levels of oCF CA 125 (> median) were significantly associated with a poor disease-free survival (DFS) (log-rank p=0.002 and p=0.005 univariate Cox-regression). Other factors associated with a poor DFS in univariate analysis were advanced FIGO stage, suboptimal debulking (both p < 0.001), high tumor grade (p=0.025), serous histology (p=0.003) and high serum (> media) CA 125 (p=0.009). In multivariate analysis, only FIGO stage was of independent predictive value. These findings indicate that, although high levels of oCF CA 125 were significantly associated with a poor Survival of EOC patients, CA 125 in oCF was not of independent predictive value and might therefore not be useful as a prognostic biomarker for EOC.
引用
收藏
页码:579 / 584
页数:6
相关论文
共 31 条
[1]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[2]   What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? [J].
Chi, D. S. ;
Eisenhauer, E. L. ;
Lang, J. ;
Huh, J. ;
Haddad, L. ;
Abu-Rustum, N. R. ;
Sonoda, Y. ;
Levine, D. A. ;
Hensley, M. ;
Barakat, R. R. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) :559-564
[3]   A prognostic model for ovarian cancer [J].
Clark, TG ;
Stewart, ME ;
Altman, DG ;
Gabra, H ;
Smyth, JF .
BRITISH JOURNAL OF CANCER, 2001, 85 (07) :944-952
[4]   Ovarian cancer [J].
Colombo, Nicoletta ;
Van Gorp, Toon ;
Parma, Gabriella ;
Amant, Frederic ;
Gatta, Gemma ;
Sessa, Cristiana ;
Vergote, Ignace .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (02) :159-179
[5]   Preoperative CA 125 levels: An independent prognostic factor for epithelial ovarian cancer [J].
Cooper, BC ;
Sood, AK ;
Davis, CS ;
Ritchie, JM ;
Sorosky, JI ;
Anderson, B ;
Buller, RE .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (01) :59-64
[6]   THE CLINICAL-SIGNIFICANCE OF PREOPERATIVE SERUM CA-125 IN OVARIAN-CANCER [J].
CRUICKSHANK, DJ ;
FULLERTON, WT ;
KLOPPER, A .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (07) :692-695
[7]   Tissue quantification of CA 125 in epithelial ovarian cancer [J].
De la Cuesta, R ;
Maestro, ML ;
Solana, J ;
Vidart, JA ;
Escudero, M ;
Iglesias, E ;
Valor, R .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (02) :106-114
[8]   CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors [J].
dos Reis, FJC ;
de Andrade, JM ;
Bighetti, S .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2002, 54 (03) :132-136
[9]   CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use [J].
Duffy, MJ ;
Bonfrer, JM ;
Kulpa, J ;
Rustin, GJS ;
Soletormos, G ;
Torre, GC ;
Tuxen, MK ;
Zwirner, M .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :679-691
[10]  
FLEUREN GJ, 1987, CANCER-AM CANCER SOC, V60, P2437, DOI 10.1002/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO